Bluebird’s Eli-Cel Gene Therapy Among Myriad New Drugs Seeking EU Approval

 
• By Neena Brizmohun

An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.

Pills
Marketing applications for new medicines have been filed for review in the EU • Source: Shutterstock

More from Product Reviews

More from Pink Sheet